ifa systems AG
- WKN: 783078
- ISIN: DE0007830788
- Land: Deutschland
Nachricht vom 12.08.2019 | 07:54
ifa systems AG: ifa systems with strong first half 2019
DGAP-News: ifa systems AG / Key word(s): Half Year Results/Change in Forecast
ifa systems with strong first half 2019
ifa systems AG, a listed specialist for health IT applications in ophthalmology, continued its successful business development in the first half of 2019 and increased sales to EUR 6.1 million (previous year EUR 3.1 million) due to license agreements of the American subsidiary Inoveon Corp. Adjusted for this effect, sales would have reached EUR 3.6 million. In addition, ifa also benefited from the introduction of telematics infrastructure in Germany in the first half of the year. The increase in sales also had a positive effect on profitability. The operating result (EBIT) rose to EUR 2.5 million, after a black zero (EUR 41 thousand) had been achieved at this point in the previous year as planned.
"The orders for our subsidiary Inoveon Corp. for the license agreements to use its database are a great success," says Jörg Polis, Chairman of the Management Board of ifa systems AG. "We were always convinced that the database contents could be used and exploited economically. With the licensing we have now found a suitable way".
The improvement in operating business was particularly evident in the area of basic licenses and runtime licenses. Basic licenses, which represent revenues with new customers or licenses for additional products from existing customers, rose to EUR 684 thousand (previous year: EUR 352 thousand) in the first half of the year, also due to the introduction of telematics infrastructure. Runtime licenses, which customers pay for the duration they use the software, also developed positively. Their share of revenues reached EUR 1.9 million, compared to EUR 1.7 million in the previous year (+ 14.2 percent).
The positive business development also had an impact on the cash flow. As of June 30, 2019, cash flow from operating activities improved by EUR 2.0 million year-on-year to EUR 1.7 million (previous year: EUR -323 thousand). After a negative free cash flow of EUR -739 thousand last year, it now amounted to EUR 1.5 million for the first half of 2019. From this result financial liabilities totalling EUR 3.0 million were repaid. Cash and cash equivalents at the end of the period amounted to EUR 2.2 million (previous year as of June 30: EUR 3.7 million).
Based on the half-year figures, the Management Board has redefined its targets for the year as a whole. For the 2019 financial year, the ifa Group now expects revenues of EUR 9.3 to 9.7 million, corresponding to the originally planned EUR 6.8 to 7.2 million from current business and the EUR 2.5 million from license agreements that cannot be planned. Neither further license agreements, which would always represent a special effect, nor possible potentials from the cooperation with NEXUS AG are considered in this planning. These will only become more concrete in the coming months.
In the medium term the prospects are also promising, as the digitization of the health care system in Germany still has a lot of potential. It can help to significantly dampen rising healthcare costs in an ageing society. The telematics infrastructure is an important step to tap this potential, and the electronic patient file is an integral part of the roadmap. Here, the ifa Group is one of the leading providers in the field of ophthalmology. And as an integration platform, it offers the possibility of connecting almost any device and any software used in practices and clinics worldwide, thus ensuring a consistent electronic workflow. The Management Board therefore assumes that the accelerated efforts in the German healthcare system will have a positive impact on the further development of the Group.
The higher revenues naturally also have a positive impact on profitability, which is why this guidance for the current financial year has also been raised. The Management Board now expects EBITDA of between EUR 3.4 million and EUR 4.2 million for the full year 2019 (previous year: EUR 1.3 million). Originally, the operating result (EBIT) based on current business was planned between EUR 0.2 and EUR 0.5 million.
Detailed information can be found in the complete Interim Report 2019. It can be downloaded from the Internet at www.ifa-systems.de, Investor Relations.
Contact for information:
Key figures as of June 30, 2019
|Company:||ifa systems AG|
|Augustinusstraße 11 b|
|Phone:||+49 (0)2234 93367-0|
|Fax:||+49 (0)2234 93367-30|
|Listed:||Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Hamburg, Munich, Stuttgart, Tradegate Exchange|
|EQS News ID:||855575|
|End of News||DGAP News Service|
ifa systems AG mit neuen Aufsichtsratsmitgliedern
Doctolib und ifa systems AG vereinbaren Kooper ...
ifa systems AG: ifa systems with strong first ...
Major order for subsidiary of ifa systems AG
Subsidiary of ifa systems AG enters into datab ...
Anleihe im Fokus
"Anleihe - Jetzt zeichnen!"
- Emissionsvolumen: bis zu 100 Mio. EUR
- Zeichnungsfrist: 11.11. bis 04.12.2019
- ISIN: DE000A2YN3Q8 / WKN: A2YN3Q
- Börsenesegment: Börse Frankfurt, Open Market (Quotation Board)
- Stückelung / Emissionspreis: 1.000 EUR/ 100%
- Zinssatz (Kupon): 5,25 %
- Laufzeit: 5 Jahre
- Fälligkeit: 5 Jahre / 6.12.2024 (vorbehaltliche vorzeitige Rückzahlung gemäß Anleihebedingungen)
- Zinszahlung: Angebot an Inhaber der 5,625 % Schuldverschreibung 2016/2021 (WKN A2AA05, ISIN DE000A2AA055) diese in die neue Anleihe zu tauschen
- Umtauschfrist: 11.11.2019 – 29.11.2019 (18.00 Uhr)
Expedeon AG mit attraktiver Produktpipeline
Durch die konsequente Fortsetzung der „Grow, Buy & Build“-Strategie hat die im Bereich der Entwicklung und Vermarktung von DNA-Technologien, Proteomik- und Antikörper-Konjugations-Anwendungen tätige Expedeon AG das Umsatzniveau angehoben und auf operativer Ergebnisebene zugleich den Break-Even nachhaltig überschritten. Für die kommenden Perioden ist der Ausbau der Umsatzerlöse mit den bestehenden Produkten geplant. Darüber hinaus verfügt die Expedeon AG über eine attraktive Produktpipeline mit hohem Umsatzpotenzial. Unser Kursziel liegt bei 3,20 € je Aktie. Das Rating lautet KAUFEN.
Der AKTIONÄR News
15. November 06:25 Amazon gegen Microsoft: Hat Amazon noch eine Chance?
14. November 15:47 Marktexperte Thomas Gebert: "Eine frohe Botschaft"
14. November 15:41 Alle reden von Tesla in Berlin (und vergessen diesen ...
14. November 15:40 Commerzbank: Was wird aus der mBank-Beteiligung?
14. November 15:02 Sixt: Die Zeit der Ernte wird kommen
News im Fokus
Henkel AG & Co. KGaA: Henkel bestätigt Ausblick für das Geschäftsjahr 2019
14. November 2019, 07:30
Conference Call zu den Neunmonatszahlen 2019
15. November 2019
Original-Research: SMT Scharf AG (von Montega AG): Kaufen
14. November 2019